PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Sexual Function & Libido

PT-141

Bremelanotide; Vyleesi

Classification: Melanocortin receptor agonist (FDA-approved)

Mechanism: MC4R agonist in CNS; induces sexual desire independent of vascular mechanisms

Benefits: Libido and arousal enhancement in HSDD (FDA-approved)

Evidence tier: FDA-Approved · Availability: Prescription

Primary sources

  1. FDA Vyleesi (bremelanotide) prescribing information
  2. Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder — two randomized phase 3 trials (RECONNECT). Obstet Gynecol 2019. PMID 31599840

Loading interactive view…